MG-132

Catalog No.S2619

MG-132 Chemical Structure

Molecular Weight(MW): 475.62

MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.

Size Price Stock Quantity  
USD 50 In stock
USD 170 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's MG-132 had a noticeably greater effect when compared with similar products from Sigma: This is directly due to using the (S, R, S) - (-) - 2 configuration.

P21 protein can be degraded through ubiquitylation pathway. Inhibition of proteasome activities results in the accumulation of P21 protein, therefore, the more powerful the inhibiting effect, the more P21 protein is accumulated. (testing protein: P21; Cell line: Hela; treatment condition: final concentration of MG-132 is 5μM, with a 6 hour treatment time)

Cited by 48 Publications

11 Customer Reviews

  • Western blot of IκBζ expression in BMDMs treated with DI and stimulated with LPS for 1 h. MG132 or bafilomycin A (BafA) were added 30 min before LPS stimulation.

    Nature, 2018, 556(7702):501-504. MG-132 purchased from Selleck.

    MDA-MB-231 cells were treated with 10 uM MG132 and incubated under normoxia or hypoxia for 4 h. Endogenous interaction between LATS2 and SIAH2 was analysed by immunoprecipitation.

    Nat Cell Biol 2015 17(1), 95-103. MG-132 purchased from Selleck.

  • HeLa cells were transfected with control mimic, RMND5A siRNA or miR-138 mimic. After transfection for 36 h, cells were treated with proteasome inhibitor MG132 (20 uM) or Dimethyl sulfoxide (DMSO) for 8 h. Endogenous Exportin-5 protein and RMND5A protein expression was measured by western blotting.

    Nucleic Acids Res 2014 42(1), 458-74. MG-132 purchased from Selleck.

    HeLa cells were transfected with negative control mimic, miR-138 mimic or RMND5A siRNA. After transfection for 36 h, cells were treated with MG132 (20 uM) or DMSO for 8 h. RMND5A and Exportin-5 protein expression were analyzed by immunocytochemistry. Nuclei were counterstained with DAPI.

    Nucleic Acids Res 2014 42(1), 458-74. MG-132 purchased from Selleck.

  •  

    TFEB induced autophagy dependent ATZ clearance in vitro. MEF transiently co-transfected with either ATZ plus GFP expressing plasmids or ATZ plus TFEB expressing plasmids were incubated with proteasome inhibitor MG132 or with DMSO for 6 h. Upon MG132 treatment, steady state levels of 52 kDa ATZ band increased in both cells transfected with ATZ plus GFP and with ATZ plus TFEB expressing plasmids. Quantification of band intensities showed a 48% reduction of ATZ in cells transfected with ATZ plus TFEB compared to cells transfected with ATZ plus GFP, in the absence of the proteasome inhibitor. In MG132 treated cells, a 61% decrease of ATZ was detected in cells transfected with ATZ plus TFEB compared to cells transfected with ATZ plus GFP.

    EMBO Mol Med 2013 5, 397-412. MG-132 purchased from Selleck.

    JAK1 expression was analyzed in A375 cells expressing scrambled shRNA or shRNF125 (#2) and treated with MG132 (5 uM, 10 hr), and in Lu1205 cells expressing WT RNF125 and treated with MG132.

    Cell Rep 2015 11(9), 1458-73. MG-132 purchased from Selleck.

  • LRB1 and LRB2 regulate phyB protein levels. PhyB protein levels in crude extracts from the wild type (WT) and the indicated mutant backgrounds were assayed by immunoblot analysis with anti-phyB monoclonal antibodies. Anti-PBA1 and anti-histone H3 antibodies were used to confirm equal protein loading. Rc-induced loss of phyB in the wild type is inhibited by 100 uM MG132.

    Plant Physiol 2012 60(1), 118-34. MG-132 purchased from Selleck.

    Representative images for γ-H2AX-stained cells treated with 100 uM FA for 3 h without or with MG132. Fluorescence was measured in at least 50 nuclei in each of three experiments.

    Toxicol Appl Pharmacol 2015 286(2), 135-41. MG-132 purchased from Selleck.

  • Nek2A impedes SuFu ubiquitination. HEK293T cells transfected with Nek2A-Myc and Flag-SuFu for 48 h were treated with MG-132 to enrich ubiquitinated proteins, and subsequently subjected to co-immunoprecipitation assay. Precipitated proteins were probed using anti-Ub antibody.

    Int J Oncol, 2017, 50(2):373-380. MG-132 purchased from Selleck.

    GSK-3β phosphorylation at Ser9 is enhanced in NOK-overexpressed stable cell lines. The proteasome inhibitor, MG132, was added in medium of HeLa-HA and HeLa-NOK-HA cells for 12 h and then the p-GSK-3b(Ser9) was assayed by western blotting.

    FEBS Lett 2012 586, 3787–3792. MG-132 purchased from Selleck.

  • Truncated mouse Period2 (Per2) protein was expressed in NIH3T3 cells, treated by cycloheximide with or without MG132 for 1-4 hours.Per2 was reported to be degraded by the proteasome proteolysis. By adding MG132 (25 μM), a proteasome inhibitor, the degradation of Per2 was dramatically decreased within 4 hours treatment (shown by western blot).

    2012 Dr. Edison DUKE-NUS Graduate Medical School Singapore.. MG-132 purchased from Selleck.

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.
Targets
20S proteasome [9]
(Cell-free assay)
100 nM
In vitro

MG-132 displays >1000 times more activity than ZLLal in inhibiting the ZLLL-MCA-degrading activity of 20S proteasome with IC50 of 100 nM versus 110 μM. MG-132 also inhibits calpain with IC50 of 1.2 μM. MG-132 induces neurite outgrowth in PC12 cells at an optimal concentration of 20 nM, displaying 500 times more potency than ZLLal. [1] MG-132 (10 μM) potently inhibits TNF-α-induced NF-κB activation, interleukin-8 (IL-8) gene transcription, and IL-8 protein release in A549 cells by inhibition of proteasome-mediated IκBα degradation. [2] MG-132 treatment potently induces p53-dependent apoptosis in KIM-2 cells by 26S proteasome inhibition. [3] Unlike BzLLLCOCHO or PS-341, MG-132 treatment results in weak inhibition of the chymotrypsinlike (CT-L) and peptidylglutamyl peptide hydrolysing (PGPH) activities of the 26S proteasome, whereas multiple myeloma cells (U266 and OPM-2) are more sensitive to induction of apoptosis by MG-132 than BzLLLCOCHO. [4] MG-132 (1 μM) sensitizes TRAIL-resistant prostate cancer cells by activating the AP-1 family members c-Fos and c-Jun, which, in turn, repress the antiapoptotic molecule c-FLIP(L). [5] MG-132 significantly enhances the ability of inositol hexakisphosphate (IP6) to reduce cellular metabolic activity in both PC3 and DU145 androgen-independent prostate cancer (AIPCa) cell lines. [6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LPS-stimulated RAW264.7 cells M1rpR2Z2dmO2aX;uJGF{e2G7 NG\VdI8zPSEQvF2= NH3F[2pFVVOR MWnJcohq[mm2czDubZRzcWNib4jp[IUheHKxZIXjeIlwdiC5aYToJGlEPTBib3[gNE4yKM7:TR?= MXmyOFY6PzR7Nh?=
HL-60 NX\vWXB2S3m2b4TvfIlkKEG|c3H5 M{fjUVQxKM7:TR?= MnPCOFghcA>? MYnEUXNQ M1zVcmlEPTB:MUCg{txO MoXXNlQ3QTd2OU[=
SMMC-7721 NF;vUJVEgXSxdH;4bYMhSXO|YYm= NFHCcmc1OCEQvF2= NGfDOWg1QCCq NXnDcXR{TE2VTx?= NIf2XGFKSzVyPUeuNUDPxE1? MVKyOFY6PzR7Nh?=
A-549 NFzvcnJEgXSxdH;4bYMhSXO|YYm= MUe0NEDPxE1? NIrRdZI1QCCq M2fmfGROW09? MXTJR|UxRDFyIN88US=> M325eFI1Pjl5NEm2
MCF-7 MVTDfZRwfG:6aXOgRZN{[Xl? NGnLWnY1OCEQvF2= NWLUboF{PDhiaB?= NFjjZ5NFVVOR NXzpR4txUUN3ME23MlMh|ryP MofJNlQ3QTd2OU[=
SW-480 M2Hzc2N6fG:2b4jpZ{BCe3OjeR?= Mnu5OFAh|ryP NInGTnk1QCCq NH30SHFFVVOR Ml3kTWM2OD12IN88US=> Ml3CNlQ3QTd2OU[=
NCI-H929 MV7DfZRwfG:6aXOgRZN{[Xl? NWTmSo5qOSEQvF2= MoHvO|IhcA>? NYDabZp6TE2VTx?= MmroTWM2OD1yLkG3JO69VQ>? M{LaZ|I1PjJ3MEi4
293T M{Tyb2N6fG:2b4jpZ{BCe3OjeR?= MY[xNEDPxE1? M2PjTlczKGh? MV;EUXNQ MoiwTWM2ODx{IN88US=> NWj0TZRROjR4MkWwPFg>
293T MnjISpVv[3Srb36gRZN{[Xl? MmHKNVAh|ryP MX2yOEBp M4fJUWROW09? MojLUY9l\XKjdHXsfUBqdmS3Y3XzJIhm[XRvc3jvZ4shKA>? NI[4W40zPDZ{NUC4PC=>
HeLa NGiwPFhMcW6jc3WgRZN{[Xl? NWDmO2Y2OTBizszN NHqweYEyKGh? MWjEUXNQ NWr6S3d7UW6mdXPld{BRSVKSIHPs[YF3[WenIHL5JIlvcGmkaYTpcocheHKxc3Xhd49u\SCjY4Tpeol1gQ>? MkHxNlQ{OjF6M{O=
MDA-MB-231 M4LxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\TZm0yKM7:TR?= MkHBO|IhcA>? MV3EUXNQ NEjQc3dKSzVyPUCuNVgh|ryP M{HvPVI1OTV|MkC2
MCF-7 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2KyRVEh|ryP NFiyWHE4OiCq NGTIWG5FVVOR MnzITWM2OD1yLkGzJO69VQ>? MYmyOFE2OzJyNh?=
MCF10A MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUKxJO69VQ>? NFu2[m04OiCq MWPEUXNQ NGX6UIJKSzVyPUCuNlkh|ryP M2TCXFI1OTV|MkC2
HEK-293 NIG5WI1McW6jc3WgRZN{[Xl? NUPUcVNUOiCjbnSgNlAh|ryP MXSyJIg> Mki4SG1UVw>? Mn\GTY5pcWKrdIOgR4hVNUxiYXP0bZZqfHlid3n0bEBKSzVyIH;mJFkhdk1i M1;v[|I{PTRyN{mw
Calu6 NInWUlZHfW6ldHnvckBCe3OjeR?= NELjWFAyOCEQvF2= NXrvOWt7OThiaB?= NVq1XpNpTE2VTx?= M2q2bnNq\26rZnnjZY51dHliYXPjeY12dGG2ZYOg[pJifGG6aX6gdJJm[3W{c3;y M1HEd|I{PTB4NEi2
IFN-gamma-induced RAW264.7 MV7GeY5kfGmxbjDBd5NigQ>? MmrRSG1UVw>? NVXwd3BmUW6qaXLpeJMhdmm2cnnjJI95cWSnIIDyc4R2[3Srb36ge4l1cCCLQ{WwJI9nKDBwMEe3JO69VQ>? NVzlR3F1OjJ{N{eyO|c>
IPC227F MUDDfZRwfG:6aXOgRZN{[Xl? MnLXNUDPxE1? NHrlcnA1QCCq MUfEUXNQ M{LHeWlEPTB;MD6wO|ch|ryP MYKyNVkzPDV{OB?=
Hepa-1c1c7 MUDGeY5kfGmxbjDBd5NigQ>? NGfTR4ozPSEQvF2= MkC2OkBp NHr5bZNFVVOR MlrBTY5kemWjc3XzJG5z\jJicILveIVqdiCuZY\lcC=> M1fxPVIxOzl{NUS0
COS-7 NFO0WVBEgXSxdH;4bYMhSXO|YYm= NYDCRZZ[OTBizszN NHLLWm9FVVOR NWTRclJLUUN3MEyxNEDPxE1? NWjHUGZVOThyOEiwPVc>
HuH-7 MkXQR5l1d3SxeHnjJGF{e2G7 NX7kTIdLOTBizszN NFTEO2xFVVOR NXPoemh7UUN3MEyxNEDPxE1? NH\RPFUyQDB6OEC5Oy=>
OCI-Ly3 MX\GeY5kfGmxbjDBd5NigQ>? M3ntR|ExKM7:TdMg MUO0JIg> NXiw[IV3TE2VTx?= M2exVGlv\HWlZYOgbJVu[W5iSXvhdJBiSmGucHjhJJN1[WKrbHn6ZZRqd25id3n0bEBGSzVyIH;mJFEh|ryP MoD0NVgxOjRzMUO=
A2780 cDDP MlLiRZBweHSxc3nzJGF{e2G7 M3LjbVI1KGh? MWDEUXNQ MmDhTY5lfWOnczDhdI9xfG:|aYOgZpkhcW6qaXLpeIlv\yCSVFXOJIRm\3KjZHH0bY9v NEDMco4yPzZ6NECxPC=>
LPS-stimulated RAW264.7 cells MnnDSpVv[3Srb36gRZN{[Xl? MlSzSG1UVw>? MomyTY5pcWKrdIOgUmYuc2GycHHCJGRPSSCkaX7kbY5o NVHRO41wOTd2MEeyO|c>
PC12 MkDtSpVv[3Srb36gRZN{[Xl? MkHtNVAxKM7:TdMg MYKyOEBp MnTrSG1UVw>? NG[xNJBKdmirYnn0d{A3NU:KRFGtJIFv\CCKMl:yMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 NXnhZYNyOTdzNUi0OVQ>
PC3 NWrDXGtVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPYeYwzOCEQvF2= M4LtNlQ5KGh? MlvBSG1UVw>? MU\JR|UxRTBwNjFOwG0> MXOxOlY5PjV|Nx?=
LP-1 NETwUItCeG:ydH;zbZMhSXO|YYm= MofRN|AxKG6P MnvMNlQhcA>? M4fnVWROW09? NWDyXXR2UW6mdXPld{BieG:ydH;zbZMh[nliaX7jdoVie2mwZzDjcIVifmWmIGDBVnAhdGW4ZXygZY5lKHKnZIXjbY5oKE2lbD2xJJBzd3SnaX6gcIV3\Wx? MkHONVU6PTh3OEm=
ES6 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvweXVyUUN3ME2wMlAyOzB4IN88US=> NFr3SIpUSU6JRWK=
A101D NUe0dFBuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlW5TWM2OD1yLkCzNlc6KM7:TR?= NXfGVWIzW0GQR1XS
OCUB-M M2DRXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTBwMEO3N|ch|ryP M3jU[XNCVkeHUh?=
LB2518-MEL MnPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTBwMEO3OkDPxE1? M3rkSXNCVkeHUh?=
SH-4 NWrQcWNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLLfXNTUUN3ME2wMlA1OzFizszN NXLiWGVWW0GQR1XS
KNS-42 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPlPI9xUUN3ME2wMlA1PDRzIN88US=> MUXTRW5ITVJ?
DSH1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTBwMEWyPFkh|ryP M3X5XXNCVkeHUh?=
NTERA-S-cl-D1 MnzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmi5TWM2OD1yLkC1O|czKM7:TR?= NF64U45USU6JRWK=
D-542MG Mn;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfsTWM2OD1yLkC1PVU4KM7:TR?= MlTlV2FPT0WU
KS-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHaW|d1UUN3ME2wMlA3PDV6IN88US=> MY\TRW5ITVJ?
BL-41 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2mzOmlEPTB;MD6wOlk1PyEQvF2= NGG3dVJUSU6JRWK=
LXF-289 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFT5VJpKSzVyPUCuNFcxPjZizszN MonnV2FPT0WU
D-247MG NX34U5J7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPjTWM2OD1yLkC3NlA6KM7:TR?= M{\ZVnNCVkeHUh?=
MMAC-SF MlLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TCV2lEPTB;MD6wO|I3QCEQvF2= NWHIUXZiW0GQR1XS
CP66-MEL M1f2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnOcWxxUUN3ME2wMlA4PSEQvF2= M4LNZnNCVkeHUh?=
LB771-HNC NYT3NZRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTBwMEiwN|Yh|ryP NETTXFJUSU6JRWK=
no-10 Mm\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjEUI5KSzVyPUCuNFg6ODlizszN MUXTRW5ITVJ?
A388 MmLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorrTWM2OD1yLkC5NFY2KM7:TR?= NXLqT3BKW0GQR1XS
OPM-2 MoC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3hTWM2OD1yLkGwOFc1KM7:TR?= MVrTRW5ITVJ?
OVCAR-4 NV;KVFdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2S0VmlEPTB;MD6xNFk{QCEQvF2= Ml3RV2FPT0WU
HOP-62 MoLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33GcGlEPTB;MD6xNFk1QSEQvF2= NIG2TXdUSU6JRWK=
ML-2 MmC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo[5TWM2OD1yLkGxPFA3KM7:TR?= MWHTRW5ITVJ?
UACC-257 NHr6RVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVO2dGJXUUN3ME2wMlEyQTJ5IN88US=> MnLXV2FPT0WU
NEC8 NHLxWJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXf6fWp2UUN3ME2wMlEyQTl3IN88US=> NUiyNXY5W0GQR1XS
ONS-76 MnnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojaTWM2OD1yLkGyPVM2KM7:TR?= NYjvUlJ[W0GQR1XS
KE-37 M1;FVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwMUOyO|gh|ryP NFPkboJUSU6JRWK=
HT-144 NIXnOotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLwTWM2OD1yLkGzPFk2KM7:TR?= NHPjUoVUSU6JRWK=
LB2241-RCC M3:3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{C5S2lEPTB;MD6xOFI1PyEQvF2= MVjTRW5ITVJ?
TE-5 MoO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHwTWM2OD1yLkG0Nlc5KM7:TR?= MnHOV2FPT0WU
KINGS-1 NVrq[ZhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXixSFdwUUN3ME2wMlE1PzlizszN MlHWV2FPT0WU
NCI-H69 M2H2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTBwMUWxOFEh|ryP MYnTRW5ITVJ?
CAS-1 NVe4SnFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILlO5BKSzVyPUCuNVU1QDJizszN NHT1cZFUSU6JRWK=
D-263MG NFPtVXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13GNmlEPTB;MD6xOlAxPiEQvF2= NI\YbotUSU6JRWK=
A253 NVm1[XF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTBwMU[xNlgh|ryP MYLTRW5ITVJ?
PF-382 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXoTWM2OD1yLkG2O|A3KM7:TR?= NWDRXpg3W0GQR1XS
CESS NXO1WHBUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTBwMUewOkDPxE1? NVP5bVl1W0GQR1XS
MZ2-MEL MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnNSGhwUUN3ME2wMlE4PTV7IN88US=> NW\FbGM{W0GQR1XS
HEL MonjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPZT5h4UUN3ME2wMlE5PTF5IN88US=> MoXJV2FPT0WU
D-392MG MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTBwMUmxNVUh|ryP MoLWV2FPT0WU
SK-LMS-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3y2RmlEPTB;MD6xPVMxOyEQvF2= MVjTRW5ITVJ?
GI-ME-N MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33vZmlEPTB;MD6xPVMxPiEQvF2= NEDTbXhUSU6JRWK=
LB831-BLC MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXBe4FbUUN3ME2wMlE6OzRizszN NWLnXnl7W0GQR1XS
DU-4475 NUXyWXNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHadGJHUUN3ME2wMlE6PjV6IN88US=> MmnlV2FPT0WU
IST-SL1 NWm2RlY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfNdm9qUUN3ME2wMlIxODl2IN88US=> M4HnO3NCVkeHUh?=
GAK NUjU[XRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvrPWh2UUN3ME2wMlIxPTN2IN88US=> NIDrc5FUSU6JRWK=
EW-1 NYLjWVdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFftWGNKSzVyPUCuNlExPDdizszN MUTTRW5ITVJ?
LAMA-84 NF7IXYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DjbmlEPTB;MD6yNVg2OSEQvF2= M2TTOnNCVkeHUh?=
SK-UT-1 MmLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\uPWk2UUN3ME2wMlIzODR7IN88US=> M2O0XHNCVkeHUh?=
VA-ES-BJ NWi4cXZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTiUJFKSzVyPUCuNlIzPTdizszN MYrTRW5ITVJ?
ACN NX7ERY1zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;mfoFMUUN3ME2wMlIzPjN6IN88US=> NWjDO|ZnW0GQR1XS
SK-PN-DW M3fpWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTBwMkOxPUDPxE1? MnLIV2FPT0WU
HD-MY-Z M4rRNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPDUmhtUUN3ME2wMlI{OzB|IN88US=> MYrTRW5ITVJ?
LB373-MEL-D NXH1TYhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\EUYJKSzVyPUCuNlQyQThizszN MWDTRW5ITVJ?
COLO-829 NH7LR2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTBwMkSyOVch|ryP M3OwV3NCVkeHUh?=
ES8 M33jO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwMkS3OlMh|ryP MlnkV2FPT0WU
RXF393 NEnnb5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHmyNHZKSzVyPUCuNlUxOTVizszN M3iwbHNCVkeHUh?=
TK10 M2XBbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHeyenRKSzVyPUCuNlU1OzVizszN MW\TRW5ITVJ?
LOUCY M37nTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTBwMkW0OVYh|ryP NGrOPWRUSU6JRWK=
MZ7-mel MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHKXIhKSzVyPUCuNlY{PzRizszN NFTGNZFUSU6JRWK=
CP67-MEL NUmxT5piT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnHZmVKSzVyPUCuNlY4OyEQvF2= MWPTRW5ITVJ?
C2BBe1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTBwMke5NFch|ryP MXTTRW5ITVJ?
K052 MoX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTBwMki5PUDPxE1? NVj6cFIxW0GQR1XS
MOLT-16 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NES5XXNKSzVyPUCuNlk2OjRizszN NFS4d2RUSU6JRWK=
KNS-81-FD NFzGUYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjaTWM2OD1yLkOwN|I{KM7:TR?= MknjV2FPT0WU
CMK M{nmOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLvfWhKSzVyPUCuN|EyOiEQvF2= NHPnVVlUSU6JRWK=
LAN-6 Mnv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHZTWM2OD1yLkOxN{DPxE1? MV;TRW5ITVJ?
KLE MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIC0dGFKSzVyPUCuN|E{ODZizszN M3\tSXNCVkeHUh?=
NCCIT Ml3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7ldYhKSzVyPUCuN|E4QDNizszN NEPFbotUSU6JRWK=
HH M1ThZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnsTWM2OD1yLkOyPFk4KM7:TR?= MkXaV2FPT0WU
TE-8 MlLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTBwM{SyO|kh|ryP NGixOmZUSU6JRWK=
GDM-1 M3rpSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTBwM{WxNFQh|ryP MU\TRW5ITVJ?
NCI-H747 M3[3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nZN2lEPTB;MD6zO|ExOyEQvF2= MofQV2FPT0WU
NCI-H1092 MlHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTBwM{i4OFQh|ryP NEnXNIVUSU6JRWK=
8-MG-BA NF\SZmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\4T2lEPTB;MD6zPVg{PyEQvF2= MkPiV2FPT0WU
NB17 NHHhWZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwNEK5O{DPxE1? MkX3V2FPT0WU
LC4-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWf2UIdLUUN3ME2wMlQ{PjB5IN88US=> NH7Mcm1USU6JRWK=
TE-1 NWT4SmxXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvjUW5KSzVyPUCuOFUyOTlizszN NIq1[21USU6JRWK=
KALS-1 MljhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTBwNE[1PFQh|ryP NHro[Y1USU6JRWK=
CCRF-CEM NUXOW3lVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTBwNEe2O|Qh|ryP MmrqV2FPT0WU
OS-RC-2 NF[3fGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDWdWNSUUN3ME2wMlQ4QTd{IN88US=> M1jHOHNCVkeHUh?=
A704 NI\CWm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXSbndKSzVyPUCuOFg3QTJizszN M{i5SnNCVkeHUh?=
BB49-HNC MojzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXexcXd{UUN3ME2wMlQ6ODl4IN88US=> NUj6T2FMW0GQR1XS
EVSA-T NXHZRYJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTBwNEm5NVEh|ryP MUPTRW5ITVJ?
Mo-T Mnu2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzzTWM2OD1yLkWxO|YzKM7:TR?= M2TLfHNCVkeHUh?=
MONO-MAC-6 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\hUmlEPTB;MD61N|YyOSEQvF2= NEnVR4NUSU6JRWK=
BB65-RCC M{XVSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIT0eVlKSzVyPUCuOVY5OTFizszN NEDpc5RUSU6JRWK=
NCI-H1882 NGjveG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvKTWM2OD1yLkW5NFM3KM7:TR?= Mo\1V2FPT0WU
TE-9 MnzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvkTWM2OD1yLk[xNFM{KM7:TR?= MlzWV2FPT0WU
NCI-H2126 NHvqOGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTBwNkK2Olkh|ryP NXnVVoZmW0GQR1XS
SF268 NH7ReGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mly0TWM2OD1yLk[1OlQyKM7:TR?= M{P3SXNCVkeHUh?=
SW872 M3LKWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTBwNkW3Nlkh|ryP MlXiV2FPT0WU
LS-513 NGHM[2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojVTWM2OD1yLk[2O|UyKM7:TR?= NX\QOWVDW0GQR1XS
NCI-H1355 NIHHZXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3mOo9KSzVyPUCuOlg3OTlizszN MXHTRW5ITVJ?
BL-70 MlTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHOO2dKSzVyPUCuOlk{QDhizszN NYD2c3hlW0GQR1XS
NCI-SNU-5 MoTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rLS2lEPTB;MD62PVU1PSEQvF2= M3zmVHNCVkeHUh?=
SNU-C2B NX3IdVVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3QZ3J[UUN3ME2wMlcxPzN7IN88US=> MlXnV2FPT0WU
GB-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjVZVZKSzVyPUCuO|IyOjRizszN NYnhRY52W0GQR1XS
CTB-1 NV3vfZpKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HjdWlEPTB;MD63O|k2PSEQvF2= NIXJeYhUSU6JRWK=
Becker MkXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3qRVNKSzVyPUCuO|k3OjFizszN NHHTZnRUSU6JRWK=
KM12 MlS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jVXWlEPTB;MD64OVQ3PiEQvF2= MnL4V2FPT0WU
ES7 NH7lOGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{P1UWlEPTB;MD64PVY2KM7:TR?= M1\ZdXNCVkeHUh?=
COLO-684 NWj5Xm9pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1i4emlEPTB;MD65NFY2QCEQvF2= MXvTRW5ITVJ?
HCC2998 M3v5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwOUO4OVQh|ryP MYXTRW5ITVJ?
TE-10 NEjBOYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGL6ZmNKSzVyPUCuPVY1OyEQvF2= M1j4d3NCVkeHUh?=
SF126 Mmf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjRT3lKSzVyPUCuPVg6PzFizszN NUO0enk4W0GQR1XS
EKVX MmrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\UTWM2OD1zLkCzOFQzKM7:TR?= M3fqXHNCVkeHUh?=
KARPAS-45 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTXTWM2OD1zLkC0NFE3KM7:TR?= MmTYV2FPT0WU
KGN NWqzbGx1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrCTpRKSzVyPUGuNFUxPDVizszN M1rKNXNCVkeHUh?=
ES1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTFwMEe5NlEh|ryP NF;WdYlUSU6JRWK=
L-540 M3\rdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXz6[2tzUUN3ME2xMlEyQDN7IN88US=> NEHDZVhUSU6JRWK=
KURAMOCHI M3\xZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjBUVBKSzVyPUGuNVI{PzRizszN MY\TRW5ITVJ?
LU-65 M3u2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLFR2xOUUN3ME2xMlEzPzV|IN88US=> M2PhSnNCVkeHUh?=
MFH-ino MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{i3bGlEPTB;MT6xO|UxOSEQvF2= M4HjSnNCVkeHUh?=
NCI-H23 MnjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\QcpZCUUN3ME2xMlIxPDFizszN MXjTRW5ITVJ?
IA-LM NIi1S4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPTTWM2OD1zLkK0NVE3KM7:TR?= MkLLV2FPT0WU
PSN1 M1e1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTFwMkewNVYh|ryP MoXjV2FPT0WU
NCI-H719 MkDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIT6eHBKSzVyPUGuNlc1OTFizszN M1jFZnNCVkeHUh?=
SW684 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTFwMki2OVkh|ryP NGXRZmVUSU6JRWK=
HCE-4 NX3Lc2hVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\rU2lEPTB;MT6zNFIzOSEQvF2= MkjTV2FPT0WU
EW-16 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoH0TWM2OD1zLkOxN|Q4KM7:TR?= MVrTRW5ITVJ?
NCI-H128 M4P0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX31dGpqUUN3ME2xMlM2QDF2IN88US=> MlPzV2FPT0WU
HC-1 MnH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfpd21HUUN3ME2xMlM5OTdizszN MW\TRW5ITVJ?
IST-MES1 M4j1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTFwNECyNFgh|ryP MoT2V2FPT0WU
Raji NFz5eXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTFwNEG4OUDPxE1? M{HjZ3NCVkeHUh?=
DMS-114 M1KyNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrqT29KSzVyPUGuOFQ2OzlizszN NHX3cJNUSU6JRWK=
GI-1 Ml:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PtUGlEPTB;MT60O|E{OSEQvF2= NHH6cFJUSU6JRWK=
NCI-H2081 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3TTWM2OD1zLkW1NVk3KM7:TR?= MnHqV2FPT0WU
LC-1F MkHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX[1b2hpUUN3ME2xMlU2OTl6IN88US=> NFjGfY1USU6JRWK=
NCI-H2227 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\OeGlEPTB;MT62NVU3OSEQvF2= NULJSldOW0GQR1XS
D-502MG MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTFwNkeyNVEh|ryP NYDJTXpCW0GQR1XS
NCI-H2141 Mkf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LBPWlEPTB;MT62O|MyPyEQvF2= NHPPTlJUSU6JRWK=
LS-411N MmO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTVSFRKSzVyPUGuOlk5ODdizszN NH7PcFNUSU6JRWK=
SU-DHL-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnX[ms4UUN3ME2xMlcyOjhzIN88US=> NELGNYtUSU6JRWK=
BB30-HNC NGjVbplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVe1NZpRUUN3ME2xMlczPjh3IN88US=> M3r4WHNCVkeHUh?=
TE-15 MkXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTFwOUKzO|Mh|ryP MU\TRW5ITVJ?
JVM-3 NVfRUlM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoS3TWM2OD1zLkmzPVA1KM7:TR?= M2jtc3NCVkeHUh?=
IST-SL2 M{\5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HQfGlEPTB;Mj6wNVI2OiEQvF2= NWjpXZZIW0GQR1XS
EW-18 M4PmOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3LZXlKSzVyPUKuNFI{OzdizszN Mk[1V2FPT0WU
DJM-1 MlfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TEOGlEPTB;Mj6wNlU2OiEQvF2= NWTyd|lsW0GQR1XS
no-11 M{X4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfwU2xbUUN3ME2yMlA{OTB2IN88US=> MYnTRW5ITVJ?
QIMR-WIL M4nYZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LOeWlEPTB;Mj6xOlc3OiEQvF2= NVvadHI3W0GQR1XS
MC-CAR MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTETWM2OD1{LkKyPVUh|ryP NVvxc2l3W0GQR1XS
KM-H2 NH7jXotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWKwfmVKUUN3ME2yMlI6ODR|IN88US=> MY\TRW5ITVJ?
ECC12 Mki2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nLTmlEPTB;Mj6zO|k1KM7:TR?= MoLTV2FPT0WU
HCE-T NXTlSVZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLlTWM2OD1{LkS0PFg{KM7:TR?= NXXrNXZ6W0GQR1XS
MFM-223 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPUPYV4UUN3ME2yMlUxQDdzIN88US=> MWfTRW5ITVJ?
SW982 MmLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTJwNUG0PEDPxE1? MkjHV2FPT0WU
KG-1 NUOwNpRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTJwOEi3PVEh|ryP MVfTRW5ITVJ?
ES4 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPmfWMyUUN3ME2zMlA3OTFzIN88US=> NHTkUGZUSU6JRWK=
SCC-3 NV7OcoRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHqydoFKSzVyPUOuNVA5PDhizszN NWnkZZhUW0GQR1XS
RH-1 NHe0dJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;5T2lEPTB;Mz6zPFc1QCEQvF2= MYHTRW5ITVJ?
NCI-H748 NVGxfmM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWWwWmxCUUN3ME2zMlQ1OjZ4IN88US=> MX;TRW5ITVJ?
HCC2218 M2TqbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnriTWM2OD1|LkS2PVM4KM7:TR?= NFnjWohUSU6JRWK=
MEG-01 M3:4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXGTWM2OD1|LkW5Olgh|ryP MknnV2FPT0WU
NB12 NGqxR2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF64OohKSzVyPUOuOVk5QDhizszN NHrO[3JUSU6JRWK=
SNB75 NHruV4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;0RlhKSzVyPUOuOlAyODNizszN NE\JfFhUSU6JRWK=
KMS-12-PE MkLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;5cY4zUUN3ME2zMlY4PzJ|IN88US=> Mkf3V2FPT0WU
SKM-1 M4rFZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DCZmlEPTB;Mz63NVM4PiEQvF2= NE\Ue|NUSU6JRWK=
COLO-320-HSR MnKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LIS2lEPTB;Mz63OVY{PCEQvF2= M3[zSnNCVkeHUh?=
NKM-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXuNYlKSzVyPUOuO|c{PzhizszN MnPqV2FPT0WU
TE-6 NYfKU3J2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFuxOJRKSzVyPUOuPVQ2PjFizszN NFvFeZJUSU6JRWK=
D-336MG NU\6fWRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTRwMEGxOlYh|ryP M3T1UnNCVkeHUh?=
NCI-H1650 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV:0TXhIUUN3ME20MlE2Pzl5IN88US=> MYLTRW5ITVJ?
ES3 M4TsW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTRwM{K4NlQh|ryP NHv5bJlUSU6JRWK=
YT M13ZUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF[4dotKSzVyPUSuN|U1OjRizszN NUDWNHF4W0GQR1XS
ES5 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzzTWM2OD12LkSwNlU2KM7:TR?= NUf0c5pYW0GQR1XS
LB647-SCLC NGDRN|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW[0TndCUUN3ME20MlU3OzB6IN88US=> Mm\hV2FPT0WU
HAL-01 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTRwNUewN|Qh|ryP M4LRR3NCVkeHUh?=
LP-1 NG\OZW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTuTWM2OD12LkeyN|cyKM7:TR?= NF65TWpUSU6JRWK=
BC-1 M3PrNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLzVFdKSzVyPUWuNFA1PDdizszN MojrV2FPT0WU
EB-3 NFXOdJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoexTWM2OD13LkCzNFQyKM7:TR?= MmP4V2FPT0WU
GT3TKB M3vHeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nKfmlEPTB;NT6xO|Y3OiEQvF2= MnnoV2FPT0WU
NCI-H209 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHhXmJKSzVyPUWuNVk{PTJizszN MXnTRW5ITVJ?
BT-474 NEfLOpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUCzNphCUUN3ME21MlI{OTB{IN88US=> MojqV2FPT0WU
RKO NY\EbmhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWSwdZNiUUN3ME21MlI{PDJ{IN88US=> NFHKU29USU6JRWK=
SIMA MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofoTWM2OD13LkOwO|Y2KM7:TR?= NUfobIhTW0GQR1XS
RL Ml7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTVwM{e1OFEh|ryP MYnTRW5ITVJ?
GCIY MorXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjwTWM2OD13LkS3NlM3KM7:TR?= MWHTRW5ITVJ?
Calu-6 MknSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDpPHpDUUN3ME21MlYzOiEQvF2= MYfTRW5ITVJ?
ALL-PO MmPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzlTItwUUN3ME21MlY{Pzl3IN88US=> M2XtbHNCVkeHUh?=
ARH-77 NWi3dpZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWewZ4FQUUN3ME21MlY4ODh5IN88US=> M3PoWXNCVkeHUh?=
A4-Fuk M37OW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVKwNmhtUUN3ME22MlA5OTF6IN88US=> M{Po[3NCVkeHUh?=
NCI-H1581 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XoeGlEPTB;Nj6yN|g1QSEQvF2= NX7TU2JIW0GQR1XS
HUTU-80 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVe1XmNoUUN3ME22MlM3QDl5IN88US=> M{DoXnNCVkeHUh?=
TGW NHXoNmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrUXpJKSzVyPU[uOFU2QTNizszN MnXoV2FPT0WU
SK-N-FI NEL0fnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTZwNEW4OVQh|ryP MXfTRW5ITVJ?
U-266 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTZwNUG5NlYh|ryP NVTrTplKW0GQR1XS
EM-2 Ml\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTZwNkewPVkh|ryP M1LQU3NCVkeHUh?=
NMC-G1 NEXWfGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17PfGlEPTB;Nj63NVg6PSEQvF2= MkHIV2FPT0WU
KASUMI-1 NGjNOpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHBcoZKSzVyPU[uPFQ4QDdizszN MUXTRW5ITVJ?
NALM-6 MnmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7Ub|dVUUN3ME22Mlg3PzV2IN88US=> NHjyXI5USU6JRWK=
OCI-AML2 NYnoe|d4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTdwMECzNlYh|ryP NV;yS|hRW0GQR1XS
SHP-77 MmXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTWW4lKUUN3ME23MlIzPDNizszN MnTVV2FPT0WU
NOMO-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLZW2x4UUN3ME23MlI1OjV2IN88US=> NIqzdldUSU6JRWK=
SK-N-DZ NEnlTI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTdwN{GwPFkh|ryP MW\TRW5ITVJ?
LB1047-RCC NEHnb2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLSTWM2OD15LkeyNlMyKM7:TR?= M{DjfXNCVkeHUh?=
MZ1-PC MoPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7iRYVKSzVyPUeuPFY2PThizszN NETw[lRUSU6JRWK=
NB10 NXfIVYh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLuTWM2OD15Lkm5OVU3KM7:TR?= MYrTRW5ITVJ?
RL95-2 MonvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3jTWM2OD16LkGwPFQzKM7:TR?= MXXTRW5ITVJ?
OMC-1 MlewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkG0TWM2OD16LkWyNVkyKM7:TR?= MXrTRW5ITVJ?
D-283MED MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37HVWlEPTB;OD65NVcyQSEQvF2= M2\vV3NCVkeHUh?=
MC116 MmTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXrNmx2UUN3ME24Mlk4QTRizszN M3vVOXNCVkeHUh?=
SJSA-1 NXTQeHJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;zTWM2OD17LkC5NFkyKM7:TR?= M2\xNHNCVkeHUh?=
JiyoyeP-2003 MkHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXOy[5RlUUN3ME25MlI6OzF5IN88US=> MUDTRW5ITVJ?
IST-MEL1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XLZ2lEPTB;OT63OFE6QCEQvF2= Mlq5V2FPT0WU
CTV-1 M2TQO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTFyLkC5O|kh|ryP NInhUVFUSU6JRWK=
NH-12 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDhTWM2OD1zMD6yOFM{KM7:TR?= NWDWelQxW0GQR1XS
CA46 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jSc2lEPTB;MUCuN|YyKM7:TR?= M4jG[3NCVkeHUh?=
NCI-SNU-1 M3nWfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fvO2lEPTB;MUCuOFk3QSEQvF2= MU\TRW5ITVJ?
SCLC-21H M4XoeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\XemlEPTB;MUCuOlU6PiEQvF2= NFnOVmhUSU6JRWK=
EC-GI-10 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTFyLkewN|Eh|ryP NW\ndHF5W0GQR1XS
SR M3f1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTFzLkCxPFUh|ryP MoriV2FPT0WU
NCI-H1648 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nwb2lEPTB;MUGuNFk3PSEQvF2= NX\aRYFNW0GQR1XS
TGBC1TKB MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWryUWJHUUN3ME2xNU41OTB{IN88US=> NV\JSGZuW0GQR1XS
EW-11 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTFzLkWxPFYh|ryP MYnTRW5ITVJ?
SK-MM-2 M4[2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPwOHdKSzVyPUGxMlgxPjFizszN NWnkNWdVW0GQR1XS
NCI-H524 NFy3ZnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXETWM2OD1zMT65PFIzKM7:TR?= Mn;uV2FPT0WU
NOS-1 NInmPZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzKTWM2OD1zMj6wN|Q2KM7:TR?= MWPTRW5ITVJ?
AM-38 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFX2PYZKSzVyPUGyMlU3OzNizszN NWrjTG16W0GQR1XS
A498 MnfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2O2OGlEPTB;MUKuO|A3QSEQvF2= NWH0[I1uW0GQR1XS
KARPAS-422 M4Tr[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorKTWM2OD1zMj63OFk3KM7:TR?= NFjhTGlUSU6JRWK=
LU-139 NWTVXW9wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHpenp3UUN3ME2xNk46ODJ4IN88US=> NUHO[XlHW0GQR1XS
COR-L88 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{i5V2lEPTB;MUKuPVM5OiEQvF2= M4P1bXNCVkeHUh?=
K5 MlrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDLTWM2OD1zMj65OFYzKM7:TR?= M13a[3NCVkeHUh?=
NB13 MlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTF{Lkm3PFMh|ryP NEHNd3JUSU6JRWK=
MRK-nu-1 MlnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkW1TWM2OD1zMz6xPVUh|ryP NXnYNnI1W0GQR1XS
MHH-NB-11 Ml7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3XTWM2OD1zMz6yPVAzKM7:TR?= Mo\4V2FPT0WU
KU812 MnnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HqO2lEPTB;MUOuOlEzPCEQvF2= MYTTRW5ITVJ?
TE-12 NHPRXYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTF|Lk[5PVQh|ryP MXLTRW5ITVJ?
NCI-N87 MmezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlL6TWM2OD1zMz63N|Yh|ryP MnvZV2FPT0WU
EB2 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;XTWM2OD1zMz64OVA2KM7:TR?= NF3m[ldUSU6JRWK=
DB NFnOb4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HkcGlEPTB;MUOuPVg5PSEQvF2= NGPY[mdUSU6JRWK=
697 M2PGPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fIXGlEPTB;MUSuOFUyOSEQvF2= NEPLNWJUSU6JRWK=
MSTO-211H M1jjSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHi2TpZKSzVyPUG0Mlc1PDhizszN NWniemUyW0GQR1XS
JVM-2 MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXS0V|ZxUUN3ME2xOE44PzN3IN88US=> NF:xV2pUSU6JRWK=
COLO-824 MljzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPzNpRWUUN3ME2xOE44QTl2IN88US=> MYHTRW5ITVJ?
BC-3 NX\3eYFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTF3LkO5PEDPxE1? NHy1c5pUSU6JRWK=
BOKU NWnuUZVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfTTWM2OD1zNT65OlA5KM7:TR?= NH;Hb4VUSU6JRWK=
GOTO MmPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvuTWM2OD1zNj65OlE4KM7:TR?= NFnuXYJUSU6JRWK=
HCC2157 NUfxSFFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVG0b2s2UUN3ME2xO{41PzV3IN88US=> M1O1SXNCVkeHUh?=
LS-1034 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfZS3B1UUN3ME2xO{43QDF6IN88US=> MWrTRW5ITVJ?
CAL-148 NESyZWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTF5Lkm3PVYh|ryP NYXrfGRNW0GQR1XS
MOLT-4 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7PPZZKSzVyPUG4MlgzODhizszN NW\UXJY4W0GQR1XS
Daudi NF7RWJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETLPG5KSzVyPUG4MlkzOzFizszN Ml\IV2FPT0WU
J-RT3-T3-5 NILVO|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7YbYlKSzVyPUG5MlQxPjZizszN NXHKXJE2W0GQR1XS
KMOE-2 M3fvT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlv4TWM2OD1zOT62OFgzKM7:TR?= NFfvbGhUSU6JRWK=
HL-60 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGi0RplKSzVyPUKwMlE6PjVizszN M17LZXNCVkeHUh?=
P31-FUJ NF7u[YZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWr0[lRMUUN3ME2yNE41PzV|IN88US=> NIj2S4tUSU6JRWK=
IM-9 NHTEVHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXZTphKSzVyPUKwMlYzOjRizszN MXXTRW5ITVJ?
HDLM-2 NYXRVXZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjoZ3RKSzVyPUKwMlg5OjFizszN MWLTRW5ITVJ?
NCI-H1304 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnOwTWM2OD1{MT6wN|EyKM7:TR?= M4\LSnNCVkeHUh?=
NCI-H345 NEXNPVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\DTWM2OD1{MT6wOlQ{KM7:TR?= MVvTRW5ITVJ?
RPMI-6666 NF7zV2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;pPWRKSzVyPUKxMlM3ODJizszN NWLWcI86W0GQR1XS
GR-ST MmPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TyTGlEPTB;MkGuOFE4KM7:TR?= M2HYTHNCVkeHUh?=
CHP-126 M4XIR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3m4OmlEPTB;MkGuOlE5OSEQvF2= MnTZV2FPT0WU
EHEB NWq3e4FsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlf2TWM2OD1{MT62O|MyKM7:TR?= M3vod3NCVkeHUh?=
CPC-N NVi0eW91T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnKTodKSzVyPUK0MlAzODFizszN MYnTRW5ITVJ?
NB1 NEfESllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTJ2Lk[5N|kh|ryP NH3MV5JUSU6JRWK=
LS-123 NFnBdohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPyXXdZUUN3ME2yOE46ODF{IN88US=> M4fMUnNCVkeHUh?=
ST486 NFfHcmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzq[5FKSzVyPUK1MlEyOTNizszN NHzjRWJUSU6JRWK=
NCI-H1963 NEexSZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vWfmlEPTB;Mk[uNFYzOyEQvF2= NEKwcm9USU6JRWK=
U-87-MG NILFVVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojKTWM2OD1{Nj63OlQ1KM7:TR?= MWfTRW5ITVJ?
COR-L279 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrWcXVKSzVyPUK2Mlc6OjJizszN NEnTNG9USU6JRWK=
LU-165 M322VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDQSYpqUUN3ME2yPE4xQDZzIN88US=> M4TFSHNCVkeHUh?=
COLO-800 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\MRWlEPTB;MkiuNlk2PiEQvF2= Mlm4V2FPT0WU
ETK-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zE[2lEPTB;MkiuN|Q1PiEQvF2= M2i4d3NCVkeHUh?=
LNCaP-Clone-FGC MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DleGlEPTB;MkmuPVI5OSEQvF2= NIPk[opUSU6JRWK=
SIG-M5 NVvRem1oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTNyLke5OVIh|ryP NVnrdGtQW0GQR1XS
NB6 NWLCRZhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPOW2Z2UUN3ME2zNE46PTB|IN88US=> NX;WdYx5W0GQR1XS
NCI-H2107 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\rNnU4UUN3ME2zNU4zOzN6IN88US=> MYPTRW5ITVJ?
SNU-C1 MnPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2H2dGlEPTB;M{GuN|EzPiEQvF2= NIrmd|BUSU6JRWK=
JAR M3\j[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HIb2lEPTB;M{GuN|c6QSEQvF2= MoDSV2FPT0WU
L-363 M2nrTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDuOFFKSzVyPUOyMlIyPDRizszN M3r6NHNCVkeHUh?=
EW-24 M3zqT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEj6c3ZKSzVyPUOyMlM1PzRizszN MYHTRW5ITVJ?
NB69 NFL2b4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPRSIh2UUN3ME2zN{43PDV2IN88US=> MXrTRW5ITVJ?
EW-13 Ml;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1j3dWlEPTB;M{OuPFk3QSEQvF2= M2[0SHNCVkeHUh?=
Ramos-2G6-4C10 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjVWlRQUUN3ME2zOE4zQTl|IN88US=> MXLTRW5ITVJ?
TE-11 MnflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7WTWM2OD1|ND60PFIzKM7:TR?= MWjTRW5ITVJ?
L-428 M4TCZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXQTWM2OD1|ND63OVM3KM7:TR?= NXrpepRRW0GQR1XS
KP-N-YN NGLCeWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrOW5M{UUN3ME2zOE46ODV5IN88US=> MVXTRW5ITVJ?
CGTH-W-1 MmW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDmTWM2OD1|Nj65NFQ5KM7:TR?= NYP3WVdkW0GQR1XS
K-562 M1j0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2[3OmlEPTB;M{euNFg3PCEQvF2= MX3TRW5ITVJ?
NCI-H1299 Ml;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37HcWlEPTB;M{iuNVYxOyEQvF2= MUfTRW5ITVJ?
RCC10RGB MoHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvxTWM2OD1|OD6yNFg{KM7:TR?= MWfTRW5ITVJ?
NCI-SNU-16 Mn73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn22TWM2OD1|OD61OlU{KM7:TR?= MUjTRW5ITVJ?
LC-2-ad MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7ZTJY4UUN3ME2zPU41OzN5IN88US=> MY\TRW5ITVJ?
MHH-PREB-1 NXHtfJpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHZTWM2OD1|OT63N|g5KM7:TR?= NG[wRpBUSU6JRWK=
NCI-H64 M3K2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTRyLkC5OFgh|ryP NH\kUo5USU6JRWK=
LB996-RCC MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFmyfopKSzVyPUSwMlg4OTZizszN MkG2V2FPT0WU
DEL MnPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XKc2lEPTB;NEGuOFQxPSEQvF2= NIj5SotUSU6JRWK=
MLMA MonXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37WR2lEPTB;NEGuO|U6PSEQvF2= MV3TRW5ITVJ?
SBC-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTR{LkG4NFYh|ryP MV\TRW5ITVJ?
MPP-89 NXvJXXFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTR{LkW4O|Uh|ryP NXPMe3JyW0GQR1XS
MV-4-11 NEXGU2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXxTWM2OD12Mj65NFY4KM7:TR?= MnT5V2FPT0WU
EoL-1- MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;DNWlEPTB;NESuNVU3QCEQvF2= M1\3NnNCVkeHUh?=
CW-2 NUDlRolvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLZTWM2OD12ND64N|QzKM7:TR?= M3PL[3NCVkeHUh?=
HT NGS0VJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrYTWM2OD12NT63NFA4KM7:TR?= NIS0bVZUSU6JRWK=
SW954 NFLEc3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPo[4FUUUN3ME20O{41OTJ6IN88US=> NX3D[5RjW0GQR1XS
A3-KAW MnXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXWzZ2VLUUN3ME20PU45ODZzIN88US=> MWjTRW5ITVJ?
TC-YIK NUTTcWM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PmVWlEPTB;NUCuNFM3OyEQvF2= M1ToO3NCVkeHUh?=
SW962 NYfUUVN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPVXXhKSzVyPUW0Mlg{PTdizszN NFK2OotUSU6JRWK=
KP-N-RT-BM-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fjbmlEPTB;NU[uOlY{QCEQvF2= MlXuV2FPT0WU
NCI-H1395 NVLrfJlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX:4OpV1UUN3ME21PE45OTd{IN88US=> MorIV2FPT0WU
RPMI-8402 NH3UfYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2r2UWlEPTB;NUiuPVUzPiEQvF2= NFHTS3NUSU6JRWK=
SCH MoW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\G[IdKSzVyPU[wMlk3OzhizszN MmniV2FPT0WU
NCI-H2196 NFHXdlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPRTWM2OD14MT6yN|Eh|ryP MnvuV2FPT0WU
LOXIMVI MonJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTZzLkiyOlYh|ryP MVfTRW5ITVJ?
TGBC24TKB MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzHXVhWUUN3ME22Nk4yPDlzIN88US=> NX\4fHRsW0GQR1XS
SK-MEL-2 M4TpT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjEXGxKSzVyPU[zMlk5QTJizszN MlnDV2FPT0WU
U-698-M NVvtVXN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIexb2ZKSzVyPU[4MlU3QDdizszN MmOyV2FPT0WU
NCI-H1522 M2\5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTZ7LkCwOFch|ryP MVjTRW5ITVJ?
UACC-812 M4r6eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTZ7LkWyNFkh|ryP NV\ubIRkW0GQR1XS
MHH-CALL-2 MkT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTdyLkC2JO69VQ>? NXjDNlN3W0GQR1XS
NB5 M{DGU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTdyLkO0Olgh|ryP M4jLeHNCVkeHUh?=
KARPAS-299 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlG4TWM2OD15MD60OFQ4KM7:TR?= M4D6eHNCVkeHUh?=
NCI-H1694 Mkf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmftTWM2OD15MT6wN|Ih|ryP NVXzNIJHW0GQR1XS
NCI-H82 MoSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DEcWlEPTB;N{GuPVUxPyEQvF2= NH\zZ29USU6JRWK=
SCC-15 M2S0PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXuzPIVEUUN3ME23Nk4{PCEQvF2= MV;TRW5ITVJ?
NCI-H1436 M4rEfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXz4Z5JxUUN3ME23Nk44PDV4IN88US=> MkDzV2FPT0WU
ATN-1 M4O1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPSNoJKSzVyPUe0MlUxPSEQvF2= M3vUb3NCVkeHUh?=
RPMI-8866 Mnz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\mSGRCUUN3ME23OE44PTB7IN88US=> MoPEV2FPT0WU
HCC1599 NIHtfppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PveGlEPTB;N{SuPFc{OiEQvF2= MVTTRW5ITVJ?
NCI-H1155 M1HTTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHD[G1KSzVyPUe0Mlk{PjdizszN M3fGVnNCVkeHUh?=
DOHH-2 M3\WbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLQTWM2OD15ND65OVE1KM7:TR?= MoP2V2FPT0WU
SK-NEP-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTd3LkC3OVQh|ryP NVHUSZZOW0GQR1XS
HCC1187 NV7XbJVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3nRWhKSzVyPUe3MlYyOjJizszN M3XuSHNCVkeHUh?=
NCI-H322M M1TsPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1G1TmlEPTB;N{iuN|cxQSEQvF2= MWfTRW5ITVJ?
NCI-H526 NVi5VohpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;1NGVKSzVyPUe4MlU5PzdizszN NVLvcGp[W0GQR1XS
NCI-H2171 NYP6XYNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\uTWM2OD15OT60NVM3KM7:TR?= M1vzPHNCVkeHUh?=
COLO-668 M3PwU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYL5VFVTUUN3ME24NU42QDh2IN88US=> NXvrNoFRW0GQR1XS
RS4-11 MnrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfrTWM2OD16Mj6yOVA2KM7:TR?= M1iycnNCVkeHUh?=
NCI-H716 NWe0WVg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;NdZloUUN3ME24Nk46ODd3IN88US=> NE\kOFhUSU6JRWK=
LU-134-A MkLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTh|LkGzOVEh|ryP NV7rWoQyW0GQR1XS
RPMI-8226 MkH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTh2LkKxNFch|ryP NFnZfHJUSU6JRWK=
KY821 MmfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3nfIJ3UUN3ME25NU43PTVzIN88US=> MVzTRW5ITVJ?
ECC4 M4HVdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXX2dndDUUN3ME25N{45OjZ7IN88US=> MWPTRW5ITVJ?
EW-3 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33TO2lEPTB;OUSuPVA5OSEQvF2= NEfPTnNUSU6JRWK=
NB7 M3vMeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37sZ2lEPTB;OUWuO|c5PiEQvF2= MVjTRW5ITVJ?
NCI-H720 NFL4[VVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnH5TWM2OD17OD60NFYyKM7:TR?= NHPyV5NUSU6JRWK=
NCI-H446 M2nNW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{P2TGlEPTB;OUmuO|U5QCEQvF2= Mn;yV2FPT0WU
NCI-H889 MoDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHsTWM2OD1zMESuNlQzKM7:TR?= NYC3SJIxW0GQR1XS
EW-22 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTFyNj6xPUDPxE1? MWTTRW5ITVJ?
BV-173 Mny3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHH5UppKSzVyPUGwPE44OjhizszN M3nNWnNCVkeHUh?=
WSU-NHL MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3zU3hSUUN3ME2xNFkvPjdzIN88US=> M{HYUXNCVkeHUh?=
MN-60 M3rwO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TJbWlEPTB;MUC5MlY6KM7:TR?= M1;aS3NCVkeHUh?=
DG-75 NHr6[|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTFzMz6zOVIh|ryP MoPuV2FPT0WU
DMS-79 NFzjfJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTFzNz6zPFIh|ryP NXi1NJY{W0GQR1XS
SK-MEL-1 MofpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmC5TWM2OD1zMUiuNFA6KM7:TR?= MW\TRW5ITVJ?
DMS-153 M3z6bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTF{MT63OFUh|ryP NX;rOnNDW0GQR1XS
NCI-H510A MmLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoryTWM2OD1zMkeuN|Ih|ryP NHiwb|dUSU6JRWK=
BE-13 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjwZ|R{UUN3ME2xN|QvODR2IN88US=> MYjTRW5ITVJ?
KP-N-YS MmPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jWWmlEPTB;MUO5Mlc{PiEQvF2= MUXTRW5ITVJ?
SUP-T1 NVnwbmJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHOTWM2OD1zNEOuO|A5KM7:TR?= M1\U[nNCVkeHUh?=
EW-12 NGSyUFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTkS2VKSzVyPUG0OE43QTlizszN NU\meWUzW0GQR1XS
NB14 NWfvfGs3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlL0TWM2OD1zNEeuNFgzKM7:TR?= M3LQenNCVkeHUh?=
MDA-MB-134-VI MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTF2OD6yOlgh|ryP MljpV2FPT0WU
NCI-H1770 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXx[YViUUN3ME2xOVYvOjd7IN88US=> MoPNV2FPT0WU
TUR NVLMOm1zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\3cmlEPTB;MU[3Mlg4KM7:TR?= MmrpV2FPT0WU
NCI-H1417 NYfIT4JZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LQUWlEPTB;MUiwMlM{OSEQvF2= NX3PZYRIW0GQR1XS
IMR-5 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rNcGlEPTB;MUixMlU4OSEQvF2= NG\NSpdUSU6JRWK=
NCI-H226 NVzqVHZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGO3OnRKSzVyPUG4PE45PjZizszN NV30eZJMW0GQR1XS
NCI-H187 M2X3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHqOFdpUUN3ME2xPVAvODZ2IN88US=> NYfENYI6W0GQR1XS
SF539 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPXdIZ7UUN3ME2xPVIvPzJ6IN88US=> MUjTRW5ITVJ?
TALL-1 NEPJN5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLLTWM2OD1zOUiuN|A1KM7:TR?= M2S4WHNCVkeHUh?=
TE-441-T Mmf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnK2TWM2OD1zOUmuO|M6KM7:TR?= MYPTRW5ITVJ?
REH NHLKcJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTJ|Nj62NlYh|ryP MYXTRW5ITVJ?
MS-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\mVnNVUUN3ME2yN|kvOTJzIN88US=> NIHrRYZUSU6JRWK=
THP-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LLUWlEPTB;Mk[0Mlc{QCEQvF2= Mkm0V2FPT0WU
NCI-H1838 NH[0fmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2CzVmlEPTB;MkexMlQ2PiEQvF2= MoDCV2FPT0WU
P30-OHK MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3se2VKSzVyPUK4N{45PDdizszN MUjTRW5ITVJ?
C8166 MknES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTN2NT6zN|gh|ryP NH\EPYlUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Administration of MG-132 effectively rescues the expression levels and plasma membrane localization of dystrophin, β-dystroglycan, α-bdystroglycan, and α-sarcoglycan in skeletal muscle fibers from mdx mice, reduces muscle membrane damage, and ameliorates the histopathological signs of muscular dystrophy. [7] MG-132 treatment significantly reduces immobilization-induced skeletal muscle atrophy in mice, by downregulating the muscle-specific ubiquitin ligases atrogin-1/MAFbx and MuRF-1 mRNA. [8]

Protocol

Kinase Assay:

[1]

+ Expand

Measurement of inhibitory activities of MG-132 against 20S proteasome:

The reaction mixture for the 20S proteasome inhibitory assay contains 0.1 M Tris-acetate, pH 7.0, 20S proteasome, MG-132, and 25 μM substrate dissolved in dimethyl sulfoxide in a final volume of 1 mL. After incuba tion at 37 °C for 15 minutes, the reaction is stopped by the addition of 0.1 mL of 10% SDS and 0.9 mL of 0.1M Tris acetate, pH 9.0. The fluorescence of the reaction products is measured. To determine the IC50 against 20S proteasome, various concentrations of MG-132 are included in the assay mixture.
Cell Research:

[3]

+ Expand
  • Cell lines: KIM-2, HC11, and ES
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 24 and 48 hours
  • Method:

    Cells are exposed to various concentrations of MG-132 for 24, and 48 hours. Supernatant and monolayer cells are harvested by centrifugation and fixed in 70% ethanol in PBS for staining with acridine orange. Equal volumes of cells and acridine orange (5 mg/mL in PBS) are mixed on a microscope slide and examined by fluorescence microscopy. For annexin V analysis, cells are harvested by centrifugation and stained with annexin V and propidium iodide. For cell cycle analysis, cells are rehydrated in PBS at room temperature for 10 minutes, followed by staining with propidium iodide (5 mg/mL). All samples are analyzed using a Coulter Epics XL flow cytometer.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: Male mdx (C57BL/10ScSn DMD mdx) mice
  • Formulation: Dissolved in DMSO, and diluted in PBS
  • Dosages: ~10 μg/kg/day
  • Administration: Injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 90 mg/mL (189.22 mM)
Ethanol 25 mg/mL (52.56 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+20% propylene glycol+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 475.62
Formula

C26H41N3O5

CAS No. 133407-82-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to know whether it contains EDTA or other chelating agent in this product(S2619)?

  • Answer:

    Our S2619 MG-132 doesn't contain EDTA or other chelating agent.

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products

Tags: buy MG-132 | MG-132 supplier | purchase MG-132 | MG-132 cost | MG-132 manufacturer | order MG-132 | MG-132 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID